GGiantBullStocks

Outlook Therapeutics, Inc. (OTLK)

NASDAQ · Healthcare

$1.38-0.72%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$71.17M
P/E ratio
EPS
Volume
6,923,290
52-week high
52-week low
Open
$1.42
Day high
$1.52
Day low
$1.37

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$1.41M-$62.42M-$1.79
2024-$75.37M-$4.06
2023-$58.98M-$4.72
2022-$66.05M-$0.31
2021-$53.16M-$0.35

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

CEO
Robert Charles Jahr
Employees
17
Country
US
IPO date
Jun 14, 2016

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Outlook Therapeutics, Inc.'s stock price today?
OTLK is trading at $1.38 as of Jul 20, 2026.
What is Outlook Therapeutics, Inc.'s market cap?
Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $71.17M.
Does Outlook Therapeutics, Inc. pay a dividend?
Outlook Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Outlook Therapeutics, Inc. in?
Outlook Therapeutics, Inc. operates in the Healthcare sector.